Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.69 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | FABP3 | P05413 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | GMNN | O75496 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31381152 | 1.00 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2NR5A2NR5A1MAPT | |
| SCHEMBL3728919 | 1.00 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2NR5A2NR5A1MAPT | |
| SCHEMBL564851 | 1.00 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2NR5A2NR5A1MAPT | |
| SCHEMBL31381151 | 0.97 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2NR5A2NR5A1MAPT | |
| SCHEMBL122604 | 0.97 | SMN1; SMN2 (0.73) | ALDH1A1SMN1; SMN2NR5A2NR5A1MAPT | |
| SCHEMBL19821335 | 0.97 | SMN1; SMN2 (0.73) | ALDH1A1SMN1; SMN2NR5A2NR5A1MAPT | |
| SCHEMBL6811206 | 0.97 | SMN1; SMN2 (0.73) | ALDH1A1SMN1; SMN2NR5A2NR5A1MAPT | |
| SCHEMBL18092159 | 0.92 | SMN1; SMN2 (0.66) | ALDH1A1SMN1; SMN2NR5A2NR5A1MAPT | |
| SCHEMBL23834444 | 0.92 | NR5A2 (0.83) | ALDH1A1SMN1; SMN2NR5A2NR5A1MAPT | |
| SCHEMBL10498201 | 0.92 | NR5A2 (0.83) | ALDH1A1SMN1; SMN2NR5A2NR5A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230302154-A1 | NANODRUGS FOR TARGETED DRUG DELIVERY AND USE THEREOF | UNIVERSITY OF CONNECTICUT | 2023-09-28 | — | — | US | disclosed |
| WO-2022040435-A1 | NANODRUGS FOR TARGETED DRUG DELIVERY AND USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-02-24 | — | — | WO | disclosed |
| EP-3357490-A1 | FUSOGENIC PROPERTIES OF SAPOSIN C AND RELATED PROTEINS AND POLYPEPTIDES FOR APPLICATION TO TRANSMEMBRANE DRUG DELIVERY SYSTEMS | Children's Hospital Medical Center (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-2020988-B1 | COMPOSITIONS COMPRISING FUSOGENIC PROTEINS OR POLYPEPTIDES DERIVED FROM PROSAPOSIN FOR APPLICATION IN TRANSMEMBRANE DRUG DELIVERY SYSTEMS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2017-08-16 | — | — | EP | disclosed |
| US-20160200784-A1 | FUSOGENIC PROPERTIES OF SAPOSIN C AND RELATED PROTEINS AND PEPTIDES FOR APPLICATION TO TRANSMEMBRANE DRUG DELIVERY SYSTEMS | CHILDREN'S HOSPITAL MEDICAL CENTER | 2016-07-14 | — | — | US | disclosed |
| US-9271932-B2 | Fusogenic properties of saposin C and related proteins and peptides for application to transmembrane drug delivery systems | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2016-03-01 | — | — | US | disclosed |
| US-20120020878-A1 | FUSOGENIC PROPERTIES OF SAPOSIN C AND RELATED PROTEINS AND PEPTIDES FOR APPLICATION TO TRANSMEMBRANE DRUG DELIVERY SYSTEMS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2012-01-26 | — | — | US | disclosed |
| US-20100311844-A1 | Spontaneously Forming Ellipsoidal Phospholipid Unilamellar Vesicles | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-12-09 | — | — | US | disclosed |
| US-20090142267-A1 | FUSOGENIC PROPERTIES OF SAPOSIN C AND RELATED PROTEINS AND PEPTIDES FOR APPLICATION TO TANSMEMBRANE DRUG DELIVERY SYSTEMS | CHILDREN'S HOSPITAL MEDICAL CENTER | 2009-06-04 | — | — | US | disclosed |
| US-20040001834-A1 | Phospholipase A2 enzyme, antibodies and inhibitors thereto | KIM, DAE-KYONG (KR) | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040001834-A1 | Phospholipase A2 enzyme, antibodies and inhibitors thereto | PLA2G4A, PLAA, PLA2G12A | ALDH1A1 1591/4885SMN1; SMN2 4301/4885NR5A2 3889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.